My career has focused on improving our understanding of mechanisms underlying ischemic heart disease (IHD) and related adverse outcomes. I have conducted extensive investigations in coronary artery disease (CAD), hypertension, treatment resistant hypertension, vascular biology, and therapeutic applications related to vascular dysfunction. My work has centered on how IHD becomes manifest with and without large coronary artery obstructive disease (CAD). Much of this work is concentrated in women with known or suspect IHD. A major goal of clinical research is development of actionable information of sufficient power to alter medical care and improve patient health by information obtained through performance of clinical trials. To this end, I conceived and led the first randomized controlled international mega-trial of blood pressure control for patients with CAD (INVEST). My experience also includes being a principal investigator (PI) in multiple NHLBI-funded projects [Women’s Ischemia Syndrome Evaluation (WISE), WISE-CVD, WISE HFpEF, MayWEST, Asymptomatic Cardiac Ischemia Pilot (ACIP), Psychophysiologic Interventions of Myocardial Ischemia (PIMI), Bypass Angioplasty Revascularization Investigation 2-Diabetes Trial (BARI2D), etc.] and many other industry-sponsored studies. More recently I have been working in cardiovascular recovery and regeneration with cell based therapies as a PI in the NHLBI Cardiovascular Cell Therapy Network (CCTRN)- 1 and 2, as well as studies funded by the the cell and gene biomedical industry.